, Tracking Stock Market Picks
Enter Symbol:
Rating: OGXI

Oncogenex Technologies Inc. (NASDAQ: OGXI) downgraded to Hold by Stifel

Wednesday,  Dec 2, 2015  8:25 AM ET by Lynn Gilbert

Stifel downgraded Oncogenex Technologies Inc. (NASDAQ: OGXI) to Hold. Previously, Stifel
rated Oncogenex Technologies Inc. (NASDAQ: OGXI) to Buy with price target $26 on 08/09/2013, when the stock price was valued at $9.55.

OncoGenex Pharmaceuticals Inc., formerly Sonus Pharmaceuticals, Inc., is a biopharmaceutical company engaged in the development and commercialization of cancer therapies that address treatment resistance in cancer patients. The Company has five product candidates in its pipeline, with each product candidate having a distinct mechanism of action and representing an opportunity for cancer drug development. OncoGenex? product candidates OGX-011, OGX-427 and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to address treatment resistance by blocking the production of specific proteins. Product candidate SN2310 is a camptothecin for the treatment of cancer. Camptothecins are potent anticancer agents that belong to the family of drugs called topoisomerase I inhibitors that bind reversibly to the TOPO-I-DNA complex causing breaks in the DNA strands during replication resulting in cell death.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy